Researchers exploring fatty liver disease have identified protective enzymes and experimental pathways that reduce liver damage, inflammation, and fibrosis in preclinical models. These findings from Texas A&M and Cedars-Sinai offer potential new targets for treating metabolic dysfunction-associated steatohepatitis.
Metabolic dysfunction-associated steatohepatitis affects millions of people by driving excess fat accumulation in the liver, which can lead to severe inflammation, tissue damage, and scarring known as fibrosis. Treatment options remain limited. Left unchecked, the progressive condition can cause cirrhosis, liver failure, and the need for a transplant.
Targeting MAP4K4 and GPPD at Texas A&M
At the Texas A&M College of Veterinary Medicine and Biomedical Sciences, Dr. Adi Joshi and his research team focused on MAP4K4, a protein involved in multiple biological pathways that act as a central regulator of disease processes. The team determined that levels of this protein increase as liver disease advances, making it a viable target for intervention. Unlike traditional approaches that attempt to lower MAP4K4 expression entirely, the experimental compound selectively blocks its activity.
This selective inhibition aims to preserve the protein’s normal functions while dampening its role in disease progression. Preclinical testing showed that the compound improved several defining characteristics of the condition simultaneously.
“We have shown in our preclinical model that targeting the MAP4K4 pathway attenuates all of the major hallmarks of MASH,” said Dr. Adi Joshi, associate professor in VMBS’ Department of Veterinary Physiology and Pharmacology. “That gives us hope that this could eventually become a useful treatment option for patients, especially those who currently have very few therapeutic options.”
Dr. Adi Joshi, associate professor in VMBS’ Department of Veterinary Physiology and Pharmacology
In addition to reducing fat accumulation, inflammation, and scarring, the research team identified a previously unknown signaling pathway through which MAP4K4 influences disease progression. The experimental therapy demonstrated an encouraging safety profile during preclinical testing. Before human clinical trials can begin, the team is investigating whether the compound improves liver disease directly or whether some of its benefits result from the weight loss observed during treatment.
Identifying UBE2N Enzyme and Mitochondrial Regulation at Cedars-Sinai
In a separate study published in Nature Metabolism, investigators co-led by Cedars-Sinai Health Sciences University identified an enzyme that helps protect the liver from severe damage. Previous research indicated that damaged mitochondria, which provide energy for cells, drive the progression of the disease. The multicenter study revealed that levels of an enzyme called UBE2N decline in liver cells as the condition advances.
“The UBE2N enzyme appears to protect the liver from the inflammation and damage associated with MASH by helping remove damaged mitochondria and supporting the breakdown of fat,” said Ekihiro Seki, MD, PhD, professor of Medicine and Biomedical Sciences at Cedars-Sinai and co-corresponding author of the study. “When levels of the enzyme fell, we saw more damaged cells and injury to the liver.”
Ekihiro Seki, MD, PhD, professor of Medicine and Biomedical Sciences at Cedars-Sinai
The findings point toward enhancing this protective pathway as a potential strategy to prevent the early form of the disease from worsening. The study was supported by grants from the National Research Foundation of Korea, the Regional Innovation System and Education programme of Chungbuk, the Pinnacle Research Award of the American Association for the Study of Liver Diseases, the San Diego Digestive Diseases Research Center, the National Institutes of Health, and the National Natural Science Foundation of China.
Pursuing New Therapeutic Approaches
Both lines of research show that metabolic liver disease must be treated by targeting multiple biological pathways rather than a single process. Experts emphasize that future investigations will need to determine how these experimental pathways can complement existing care strategies.
“Future studies can test whether enhancing this protective pathway can complement existing treatments, identify patients most likely to benefit and lead to new therapeutic approaches for preventing advanced disease.”
Shelly Lu, MD, the Women’s Guild Chair in Gastroenterology and director of the Karsh Division of Gastroenterology and Hepatology at Cedars-Sinai
As Texas A&M researchers investigate the effects of the GPPD compound and Cedars-Sinai investigators explore mitochondrial regulation mechanisms, the findings lay a strong preclinical foundation for new therapeutic interventions aimed at halting advanced liver failure.